Literature DB >> 23486750

SMRI contributions to drug development for schizophrenia and bipolar disorder.

E Fuller Torrey, Jana C Bowcut.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23486750      PMCID: PMC3627777          DOI: 10.1093/schbul/sbt039

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  3 in total

1.  Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial.

Authors:  Konasale M Prasad; Shaun M Eack; Matcheri S Keshavan; Robert H Yolken; Satish Iyengar; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2012-03-23       Impact factor: 9.306

Review 2.  Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas.

Authors:  E Fuller Torrey; John M Davis
Journal:  Clin Schizophr Relat Psychoses       Date:  2012-01

3.  The stanley neuropathology consortium integrative database: a novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers.

Authors:  Sanghyeon Kim; Maree J Webster
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

  3 in total
  1 in total

1.  An association between the reduced levels of SLC1A2 and GAD1 in the dorsolateral prefrontal cortex in major depressive disorder: possible involvement of an attenuated RAF/MEK/ERK signaling pathway.

Authors:  Dong Hoon Oh; Daeyoung Oh; Hyeon Son; Maree J Webster; Cyndi S Weickert; Seok Hyeon Kim
Journal:  J Neural Transm (Vienna)       Date:  2014-03-22       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.